Company intelligence / Profile preview
Altheos, Inc.
South San Francisco, California, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Altheos conducted Phase 1/2a and Phase 2a clinical trials for its lead compound ATS907, a ROCK-selective inhibitor for reducing elevated intraocular pressure in glaucoma and ocular hypertension. The company appears to be out of business now.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Asahi Kasei Pharma (licensed ROCK inhibitor compounds)
Beyond the preview
Go deeper on Altheos, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altheos, Inc..